Novavax, Inc.

NVAX Healthcare Biotechnology

Novavax, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.1 billion, up 64.7% from fiscal 2024. In the quarter to June 2026, revenue fell 76.3%, EPS fell 148.5%, free cash flow grew 43.0% and total debt rose 31.5%, each against the same quarter a year earlier.

11.26 1.56 −12.17%
Market cap
$2.1B
P/E
0.0×
Fwd P/E
−21.7×
Dividend yield
—
F-score
5/9
Altman Z
−2.18
Beneish M
0.39
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
323.66% 79.70% (117.16%) (100.06%)

+8 more TTM periods

Piotroski F-Score
1 1 5 5
ROA
(21.62%) (7.52%) 32.17% 23.63%
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(51.76%) (15.96%) 78.19% 57.55%
Average Days of Receivables
16.53 14.27 34.58 11.72
Free Cash Flow per Share
(0.26) (0.59) (1.56) (1.19)
Free Cash Flow
(42.20) (96.79) (252.05) (193.10)
Other line items

Show all line items

Columns are period end dates